1
|
Song CY, Ghafoor K, Ghafoor HU, Khan NS, Thirunavukkarasu S, Jennings BL, Estes AM, Zaidi S, Bridges D, Tso P, Gonzalez FJ, Malik KU. Cytochrome P450 1B1 Contributes to the Development of Atherosclerosis and Hypertension in Apolipoprotein E-Deficient Mice. Hypertension 2015; 67:206-13. [PMID: 26573711 PMCID: PMC4672747 DOI: 10.1161/hypertensionaha.115.06427] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 10/20/2015] [Indexed: 01/24/2023]
Abstract
Supplemental Digital Content is available in the text. Cytochrome P450 (CYP) 1B1 contributes to vascular smooth muscle cell growth and hypertension in male mice. This study was conducted to determine the contribution of CYP1B1 to the development of atherosclerosis and hypertension and associated pathogenesis in 8-week-old male apolipoprotein E–deficient (ApoE−/−/Cyp1b1+/+), and ApoE- and CYP1B1-deficient (ApoE−/−/Cyp1b1−/−) mice fed a normal or atherogenic diet for 12 weeks. A separate group of ApoE−/−/Cyp1b1+/+ mice on an atherogenic diet was injected every third day with the CYP1B1 inhibitor, 2,3′,4,5′-tetramethoxystilbene (300 μg/kg), or its vehicle, dimethyl sulfoxide (30 μL, IP); systolic blood pressure was measured by the tail cuff method. After 12 weeks, mice were euthanized, blood collected for lipid analysis, and aortas harvested for measuring lesions and remodeling, and for infiltration of inflammatory cells by histological and immunohistochemical analysis, respectively, and for reactive oxygen species production. Blood pressure, areas of lipids and collagen deposition, elastin breaks, infiltration of macrophages and T lymphocytes, reactive oxygen species generation in the aorta, and plasma lipid levels were increased in ApoE−/−/Cyp1b1+/+ mice on an atherogenic diet; these changes were minimized in mice given 2,3′,4,5′-tetramethoxystilbene, and in ApoE−/−/Cyp1b1−/− mice on an atherogenic diet; absorption/production of lipids remained unaltered in these mice. These data suggest that aortic lesions, hypertension, and associated pathogenesis in ApoE−/−/Cyp1b1+/+ mice on an atherogenic diet are most likely dependent on CYP1B1-generated oxidative stress and increased plasma lipid levels independent of blood pressure and absorption of lipids. CYP1B1 could serve as a novel target for developing drugs to treat atherosclerosis and hypertension caused by hypercholesterolemia.
Collapse
Affiliation(s)
- Chi Young Song
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Khuzema Ghafoor
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Hafiz U Ghafoor
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Nayaab S Khan
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Shyamala Thirunavukkarasu
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Brett L Jennings
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Anne M Estes
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Sahar Zaidi
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Dave Bridges
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Patrick Tso
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Frank J Gonzalez
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)
| | - Kafait U Malik
- From the Department of Pharmacology (C.Y.S., K.G., H.U.G., N.S.K., S.T., B.L.J., A.M.E., S.Z., K.U.M.) and Department of Physiology and Pediatrics (D.B.), College of Medicine, University of Tennessee Health Science Center, Memphis; Department of Pathobiology and Molecular Medicine, University of Cincinnati, OH (P.T.); and Center for Cancer Research, Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
| |
Collapse
|